TNS4: A novel drug target and biomarker for the treatment of neurodegenerative diseases

Target Name: TNS4

NCBI ID: G84951

TNS4

TNS4: A novel drug target and biomarker for the treatment of neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are debilitating and life-threatening conditions that affect millions of people worldwide. These conditions are characterized by the progressive loss of brain cells, leading to a wide range of symptoms, including cognitive decline, behavioral changes, and progressive muscle weakness.

Tensin 4 (TNS4) is a protein that has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. In this article, we will discuss the discovery, function, and potential clinical applications of TNS4.

Discovery and Function of TNS4

TNS4 is a member of the Tensin family, which includes several structurally similar proteins that are involved in various cellular processes, including cell signaling, cell adhesion, and cytoskeletal organization. The Tensin family has been identified as a potential drug target due to its involvement in various diseases, including neurodegenerative diseases.

The function of TNS4 is to regulate the actinin cytoskeleton, which is a protein that plays a critical role in the structure and function of cells. TNS4 is involved in the regulation of actinin cytoskeleton dynamics, which is crucial for the proper functioning of cells, including the regulation of cell division, differentiation, and movement.

In addition to its role in actinin cytoskeleton regulation, TNS4 has also been shown to play a role in the regulation of cell signaling pathways, including the regulation of the JAK/STAT signaling pathway. This pathway is involved in the regulation of immune and inflammatory responses, and is implicated in the development and progression of various diseases, including neurodegenerative diseases.

Potential Clinical Applications of TNS4

The potential clinical applications of TNS4 are vast and varied. One of the primary goals of studying TNS4 is to develop it as a drug target for the treatment of neurodegenerative diseases. By targeting TNS4 with small molecules or antibodies, researchers hope to improve the treatment of these debilitating conditions.

In addition to its potential as a drug target, TNS4 has also been shown to be a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The regulation of actinin cytoskeleton dynamics is a critical factor in the development and progression of these conditions, and may be an useful biomarker for the assessment of disease severity and response to therapeutic interventions.

Conclusion

TNS4 is a protein that has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. Its role in actinin cytoskeleton regulation and its involvement in cell signaling pathways make it an attractive target for small molecule and antibody-based therapies. Further research is needed to fully understand the potential clinical applications of TNS4 and to develop safe and effective treatments for neurodegenerative diseases.

Protein Name: Tensin 4

Functions: Promotes EGF-induced cell migration by displacing tensin TNS3 from the cytoplasmic tail of integrin ITGB1 which results in dissociation of TNS3 from focal adhesions, disassembly of actin stress fibers and initiation of cell migration (PubMed:17643115). Suppresses ligand-induced degradation of EGFR by reducing EGFR ubiquitination in the presence of EGF (PubMed:23774213). Increases MET protein stability by inhibiting MET endocytosis and subsequent lysosomal degradation which leads to increased cell survival, proliferation and migration (PubMed:24814316)

The "TNS4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNS4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets